Rezolute Inc (NAS:RZLT)
$ 4.41 -0.03 (-0.68%) Market Cap: 255.53 Mil Enterprise Value: 149.34 Mil PE Ratio: 0 PB Ratio: 2.15 GF Score: 35/100

Rezolute Inc at Jefferies London Healthcare Conference Transcript

Nov 17, 2022 / 04:25PM GMT
Release Date Price: $1.71 (-2.01%)
Kevin Strang
Jefferies - Analyst

My name is Kevin Strang. I'm one of the biotech associates here at Jefferies. It's my pleasure to be here for a fireside chat with Nevan Elam from Rezolute Bio, the Founder and CEO. And yes, thank you for joining us today.

And just to hop into the fireside chat, for those that may be new to the story, could you provide a one-minute intro to Rezolute Bio?

Nevan Elam
Rezolute, Inc. - CEO & Founder

Sure. Thanks, Kevin. And it's a pleasure to be here and to share a little bit of our story here at the conference. At Rezolute Bio we're focused on glucose imbalance, diseases associated with glucose imbalance on a couple of ends of the spectrum. One end of the spectrum is a very rare disease, very problematic pediatric indication where there's not enough glucose that's available for the children at birth. And the disease is congenital hyperinsulinism. It's the overexpression of insulin such that liver fat and muscle uptake glucose and really starve the brain of much-needed glucose.

Serious complications arise

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot